LikeMinds
LikeMinds is a Boston-based brain health company pursuing accurate, affordable, and accessible diagnosis and treatment of tremor and dementia disorders, including Parkinson's Disease and Lewy Body Dementia, leveraging a credentialed advisory board spanning MIT, Johns Hopkins, and former pharma executives.
- Company typePrivate
- Founded2016
- HeadquartersBoston, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
What LikeMinds does
LikeMinds is a privately-held, Delaware-incorporated brain health company headquartered at 361 Newbury Street in Boston, founded in 2016 with 1-10 employees. The company's stated mission is the accurate, affordable, and accessible diagnosis and treatment of tremor and dementia disorders, including Parkinson's Disease and Lewy Body Dementia, with positioning that frames it as a single entity operating across both the detection and treatment sides of these dopamine-related conditions. The website (copyright 2024) and SEC filings through 2021 indicate active operation, but the input data discloses no specific products, no proprietary technology platform, no app or API surface, no pricing model, no customer logos, no commercial partnerships, and no patents or trademarks. Two SEC exempt offerings — $522,671 in 2018 and $1,146,042 with first sale 2021-05-28 — represent the entirety of disclosed capital formation, with no venture or institutional investor identified.
The company appears to operate as a clinical and scientific platform rather than a commercial product entity at present. Its differentiation is anchored in an unusually credentialed advisory and board roster for a company of this size: Chairman and CEO Peter G. Savas brings prior leadership of Alseres Pharmaceuticals, Aderis Pharmaceuticals (developer of the Neupro transdermal patch for Parkinson's and Restless Legs Syndrome), and Unisyn; Robert Langer (MIT) chairs Science and Intellectual Property; Henry Brem chairs Neurosurgery at Johns Hopkins; Paul Sekhri (formerly Teva, TPG Biotech) chairs Compensation; Gary Frashier (former OSI Pharmaceuticals CEO) and Robert Van Nostrand (former OSI CFO) chair Finance and Audit; and Heiner Dreismann (former CEO of Roche Molecular Systems) advises on diagnostics. There is also an unreferenced Executive Vice President / Chief Scientific & Medical Officer on the leadership roster. The revenue model, customer segmentation, pricing mechanics, and go-to-market are not publicly disclosed, and the source data offers no evidence of commercial sales, recurring revenue, or contracted customers.
LikeMinds firmographics
Firmographics- Name
- LikeMinds
- Legal name
- LikeMinds, Inc.
- Website
- https://likeminds.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- LikeMinds is a Boston-based brain health company pursuing accurate, affordable, and accessible diagnosis and treatment of tremor and dementia disorders, including Parkinson's Disease and Lewy Body Dementia, leveraging a credentialed advisory board spanning MIT, Johns Hopkins, and former pharma executives.
- Ownership category
- akta.pro rank
LikeMinds industry classification
Industry- Product category
- Neurological Therapeutics and Diagnostics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Neurology RPM (epilepsy, Parkinson’s, MS monitoring) (HLALAFAJ)
- akta.pro secondary industries
- Cognitive & Behavioral Neurology (Dementia/Memory Disorders) (HLAKAIAH), Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables) (HLAHACAE)
Keywords
Where LikeMinds is headquartered
LocationHeadquarters
- HQ city
- Boston
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
LikeMinds business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations
LikeMinds product offering
Product offeringCore offering
LikeMinds is advancing the study, detection, and treatment of dopamine-related brain disorders, with a primary focus on Parkinson's Disease and Lewy Body Dementia. The company is developing diagnostic and treatment capabilities positioned as accurate, affordable, and accessible solutions for tremor and dementia disorders. No specific named, commercially available products or services are evidenced in the source data.
Product overview
LikeMinds is a brain health company focused on the diagnosis and treatment of tremor and dementia disorders, positioning itself as providing accurate, affordable, and accessible solutions in this therapeutic area.
Differentiator
Problem solved
Functional benefit
Companies that use LikeMinds
Customer profileSegments1 record
Ideal customer profiles1 record
LikeMinds technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
LikeMinds partnerships and signals
Strategic signalScale indicators1 record
Recent moves4 records
Expansion highlights2 records
LikeMinds competitors and assessment
Company assessmentDirect peers
- Acadia Pharmaceuticals: Acadia commercializes Nuplazid (pimavanserin), the only FDA-approved therapy for Parkinson's disease psychosis and widely used off-label in Lewy Body Dementia. Directly comparable focus on dopamine-related brain disorders with both diagnostic positioning and approved treatment.
- Cerevel Therapeutics: Cerevel was a clinical-stage neuroscience company focused on Parkinson's disease and other CNS disorders (acquired by AbbVie for ~$8.7B in 2024). Closely comparable CNS/Parkinson's therapeutic focus and similar early-stage-to-commercialization trajectory.
- Prevail Therapeutics: Prevail developed AAV-based gene therapies for Parkinson's disease and other neurodegenerative disorders and was acquired by Eli Lilly in 2021. Directly comparable focus on disease-modifying approaches for Parkinson's with similar early-stage biotech structure.
- Prothena Corporation: Prothena is a clinical-stage neuroscience company developing therapies for neurodegenerative diseases including Parkinson's and related synucleinopathies. Comparable focus on protein-misfolding-driven brain disorders adjacent to Lewy Body Dementia.
Emerging players
- Cortexyme: Cortexyme developed therapies targeting bacterial proteases implicated in neurodegeneration including Alzheimer's and related dementias. Comparable small-cap brain health biotech addressing dementia with disease-modifying intent.
- Sage Therapeutics: Sage Therapeutics develops CNS therapies including Zurzuvae (postpartum depression) with a broader neurology pipeline. Comparable small-cap neuroscience biotech pursuing novel mechanisms in brain health.
Broad incumbents
- Biogen: Biogen is a large biopharmaceutical company with a major focus on neurodegenerative diseases including Alzheimer's and Parkinson's. Comparable therapeutic-area focus, though at vastly greater scale and with broader portfolio.
- AbbVie: AbbVie markets Duopa and Vyalev for Parkinson's disease and acquired Cerevel Therapeutics in 2024 to expand its neuroscience pipeline. Comparable Parkinson's franchise and broad CNS portfolio.
- Roche: Roche has a major molecular diagnostics franchise (relevant to LikeMinds' diagnostic focus via advisor Heiner Dreismann) and CNS/neuroscience drug programs including Parkinson's and dementia. Broadly comparable on both Dx and neuro-therapeutic axes.
- Teva Pharmaceutical Industries: Teva markets Austedo/Austedo XR for chorea in Huntington's and Parkinson's-related movement disorders and has broader CNS operations. Comparable large-pharma presence in movement disorders and tremor-related indications.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat2 records
Key risks7 records
Key highlights4 records
Customer concentration
LikeMinds social profiles
Digital presenceLikeMinds financial estimates
Financial estimateRevenue estimate
Valuation estimate
LikeMinds leadership team
Management profileNumber of profiles
Profiles7 records
LikeMinds funding detail
Funding detailFunding overview
Funding rounds2 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
LikeMinds M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about LikeMinds
What does LikeMinds do?
LikeMinds is advancing the study, detection, and treatment of dopamine-related brain disorders, with a primary focus on Parkinson's Disease and Lewy Body Dementia. The company is developing diagnostic and treatment capabilities positioned as accurate, affordable, and accessible solutions for tremor and dementia disorders. No specific named, commercially available products or services are evidenced in the source data.
Is LikeMinds a public or private company?
LikeMinds is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was LikeMinds founded?
LikeMinds was founded in 2016. It employs 1 to 10 people.
Where is LikeMinds based?
LikeMinds is headquartered in Boston, United States, in the North America region.
Who are LikeMinds's main competitors?
Direct peers on record are Acadia Pharmaceuticals, Cerevel Therapeutics, Prevail Therapeutics and Prothena Corporation. Emerging players are Cortexyme and Sage Therapeutics. Broad incumbents are Biogen, AbbVie, Roche and Teva Pharmaceutical Industries.
Does LikeMinds have an API?
No public API is recorded for LikeMinds.
What industry is LikeMinds in?
LikeMinds's product category is Neurological Therapeutics and Diagnostics. Its primary akta.pro industry code is HLALAFAJ, Neurology RPM (epilepsy, Parkinson’s, MS monitoring), with a secondary code of HLAKAIAH, Cognitive & Behavioral Neurology (Dementia/Memory Disorders). Its NAICS code is 541714 and its SIC code is 8731.